CVT Cases Turn up in Patients Vaccinated with mRNA-based Vaccine: a Black Swan or Predictable Event?

25/06/2021

Published 21 Jun 2021 TrialSite News

This case series reported on patients in Singapore and associated ultra-rare CVT with post-mRNA-based COVID-19 vaccination. Led by the corresponding author Bingwen Eugene Fan, Department of Hematology, Tan Tock Seng Hospital in Singapore and colleagues, the case series published as a correspondence acknowledges COVID-19's strong association with immunothrombosis that can lead to deadly conditions from stroke to CVT.

The authors suggest that "CVT occurring post COVID-19 mRNA vaccination could be a possible recapitulation of the thrombotic complications seen in acute COVID-19 vaccination itself may be associated with an increased risk of developing COVID-19-like disease or its complications."

Of interest, the authors noted, "While the SARS-COV-2 virion has a higher thrombogenic potential, the spike glycoprotein also carries significant thrombogenicity. We, therefore, postulate that the pathogenesis of BNT162b2 mRNA vaccine-induced CVT may possibly be related to spike glycoprotein interaction causing immunothrombosis," which the authors point out arise from the following:

  • Disruption of endothelial homeostasis and the blood-brain barrier
  • SARS-CoV-2 spike glycoprotein directly causing platelet activation
  • Aberrant activation of the alternative pathway of complement

Robert Malone, a TrialSite advisory committee member, shared recently on the topic of the mRNA-based COVID-19 vaccines that first the "data strongly indicate that the experimental vaccines, including the mRNA and recombinant adenoviral vaccines, have saved lives many lives." But Dr. Malone also emphasized that "it is also increasingly clear that there are some risks associated with these vaccines. Various governments have attempted to deny that this is the case. But they are wrong. Vaccination-association coagulation is a risk. Cardiotoxicity is a risk. Those are proven, and discussed in official U.S. Government communications, as well as communications from a variety of other governments."

Malone, in suggesting the incidents reported in Singapore are associated with many more adverse events and deaths than the government, industry or media is sharing, declared recently in a public entry, "Based on what I have seen, I believe the other toxicity risks will become more apparent. These include menstrual irregularities, development of thrombocytopenia, cerebrovascular effects, and reactivation of latent viruses such as clinical shingles."

Participating researchers from Singapore come from a number of prominent institutions, including, of course, Tan Tock Seng Hospital, Khoo Teck Puat Hospital as well as the National Neuroscience Institute.

Lead Research/Investigator

Bingwen Eugene Fan, Department of Hematology, Tan Tock Seng Hospital in Singapore (Corresponding Author)